'We sim­ply can­not sus­tain': Idor­sia weighs lay­offs, deals, pipeline trims to bring cost down

Idor­sia could cut “up to 500 po­si­tions” in R&D and as­so­ci­at­ed sup­port func­tions as the Swiss drug­mak­er finds ways to save cash un­til it can turn things around with its in­som­nia drug, Qu­viviq.

The cost re­duc­tion ini­tia­tive car­ries the am­bi­tious goal of chop­ping cash burn at its Allschwil head­quar­ters by half, start­ing ear­ly next year. To that end, it will re­view the pipeline and prod­uct port­fo­lio to find any projects that can ei­ther be halt­ed or hand­ed off through deals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER